William Blair initiated CareDx with Market Perform, citing LCD uncertainty. Shares trade at a 67% discount to peers, fair value pegged near $20. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here → CareDx, Inc.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics, Inc.

Investors need to pay close attention to CDNA stock based on the movements in the options market lately.

CareDx ( NASDAQ:CDNA ) , a molecular diagnostics company specializing in transplant care solutions, released its results for the second quarter of fiscal 2025 on August 6, 2025. The big news from the release was a solid beat on non-GAAP earnings per share, reporting $0.10 against an expected ...

CareDx (CDNA) delivered earnings and revenue surprises of -16.67% and -4.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

SAN DIEGO, May 21, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. CDNA for potential breaches of fiduciary duties and violations of the federal securities laws.

CareDx (CDNA) delivered earnings and revenue surprises of 50% and 0.30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?